欧洲皮肤癣菌病新出现的抗真菌治疗失败：需加以关注，否则可能会成为地方病。
Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic.
作者信息
Saunte D M L, Pereiro-Ferreirós M, Rodríguez-Cerdeira C, Sergeev A Y, Arabatzis M, Prohić A, Piraccini B M, Lecerf P, Nenoff P, Kotrekhova L P, Bosshard P P, Padovese V, Szepietowski J C, Sigurgeirsson B, Nowicki R J, Schmid-Grendelmeier P, Hay R J
机构信息
European Academy of Dermatology and Venereology TASK force on Mycology.
Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
出版信息
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1582-1586. doi: 10.1111/jdv.17241. Epub 2021 Apr 22.
BACKGROUND
Dermatophytosis is a world-wide distributed common infection. Antifungal drug resistance in dermatophytosis used to be rare, but unfortunately the current Indian epidemic of atypical widespread recalcitrant and terbinafine-resistant dermatophytosis is spreading and has sporadically been reported in Europe.
OBJECTIVES
To explore the occurrence of clinical and mycological proven antifungal drug resistance in dermatophytes in Europe.
METHODS
A standardized questionnaire was distributed through the EADV Task Force of Mycology network to dermatologists in Europe.
RESULTS
Representatives from 20 countries completed the questionnaires of which 17 (85 %) had observed clinical and/or mycological confirmed antifungal resistance, two countries published cases of antifungal resistance and one country had no known cases.
CONCLUSIONS
This pilot study confirms that both clinical and mycological antifungal resistance exist in Europe.
背景
皮肤癣菌病是一种全球分布的常见感染。皮肤癣菌病中的抗真菌药物耐药性过去较为罕见，但不幸的是，目前印度流行的非典型广泛顽固性和特比萘芬耐药性皮肤癣菌病正在蔓延，并且在欧洲也有零星报道。
目的
探讨欧洲皮肤癣菌中临床和真菌学证实的抗真菌药物耐药性的发生情况。
方法
通过欧洲皮肤性病学会真菌学网络特别工作组向欧洲皮肤科医生分发标准化问卷。
结果
来自20个国家的代表完成了问卷，其中17个国家（85%）观察到临床和/或真菌学证实的抗真菌耐药性，两个国家发表了抗真菌耐药性病例，一个国家没有已知病例。
结论
这项初步研究证实欧洲存在临床和真菌学抗真菌耐药性。
Zotero 插件